Cargando…

Comparison of Cytomegalovirus-Specific Immune Cell Response to Proteins versus Peptides Using an IFN-γ ELISpot Assay after Hematopoietic Stem Cell Transplantation

Cytomegalovirus (CMV) infection is a major cause of morbidity and mortality following hematopoietic stem cell transplantation (HSCT). Measuring CMV-specific cellular immunity may improve the risk stratification and management of patients. IFN-γ ELISpot assays, based on the stimulation of peripheral...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wagner-Drouet, Eva, Teschner, Daniel, Wolschke, Christine, Schäfer-Eckart, Kerstin, Gärtner, Johannes, Mielke, Stephan, Schreder, Martin, Kobbe, Guido, Hilgendorf, Inken, Klein, Stefan, Verbeek, Mareike, Ditschkowski, Markus, Koch, Martina, Lindemann, Monika, Schmidt, Traudel, Rascle, Anne, Barabas, Sascha, Deml, Ludwig, Wagner, Ralf, Wolff, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919014/ https://www.ncbi.nlm.nih.gov/pubmed/33671952 http://dx.doi.org/10.3390/diagnostics11020312

Ejemplares similares

Standardized monitoring of cytomegalovirusspecific immunity can improve risk stratification of recurrent cytomegalovirus reactivation after hematopoietic stem cell transplantation
por: Wagner-Drouet, Eva, et al.
Publicado: (2019)

1575. Clinical Validation of a Novel ELISpot-based in vitro Diagnostic Assay to Monitor CMV-Specific Cell-Mediated Immunity in SOT and HSCT Immunocompromised Patients
por: Banas, Bernhard, et al.
Publicado: (2018)

An optimized IFN-γ ELISpot assay for the sensitive and standardized monitoring of CMV protein-reactive effector cells of cell-mediated immunity
por: Barabas, Sascha, et al.
Publicado: (2017)

Comparison of SARS-CoV-2- and HCoV-Specific T Cell Response Using IFN-γ ELISpot
por: Thümmler, Laura, et al.
Publicado: (2021)

Performance of serum-supplemented and serum-free media in IFNγ Elispot Assays for human T cells
por: Janetzki, Sylvia, et al.
Publicado: (2009)

Modified ELISPOT: Modifications of the Elispot Assay for T Cell Monitoring in Cancer Vaccine Trials
por: Malyguine, Anatoli
Publicado: (2005)

Precision and linearity targets for validation of an IFNγ ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides
por: Maecker, Holden T, et al.
Publicado: (2008)

Reversion and conversion of Mycobacterium tuberculosis IFN-γ ELISpot results during anti-tuberculous treatment in HIV-infected children
por: Connell, Tom G, et al.
Publicado: (2010)

Validation of an IFN-gamma ELISpot assay to measure cellular immune responses against viral antigens in non-human primates
por: Yang, Fan, et al.
Publicado: (2021)

Fludarabine/TBI 8 Gy versus fludarabine/treosulfan conditioning in patients with AML in first complete remission: a study from the Acute Leukemia Working Party of the EBMT
por: Bug, Gesine, et al.
Publicado: (2023)

The Cytomegalovirus-Specific IL-21 ELISpot Correlates with Allograft Function of Kidney Transplant Recipients
por: Lindemann, Monika, et al.
Publicado: (2018)

Nickel, palladium and rhodium induced IFN-gamma and IL-10 production as assessed by in vitro ELISpot-analysis in contact dermatitis patients
por: Bordignon, Valentina, et al.
Publicado: (2008)

Potential Role of M. tuberculosis Specific IFN-γ and IL-2 ELISPOT Assays in Discriminating Children with Active or Latent Tuberculosis
por: Chiappini, Elena, et al.
Publicado: (2012)

Improvement of IFNγ ELISPOT Performance Following Overnight Resting of Frozen PBMC Samples Confirmed Through Rigorous Statistical Analysis
por: Santos, Radleigh, et al.
Publicado: (2014)

Pretransplant Donor-specific IFNγ ELISPOT as a Predictor of Graft Rejection: A Diagnostic Test Accuracy Meta-analysis
por: Montero, Nuria, et al.
Publicado: (2019)

Establishment of an ELISpot Assay to Detect Cellular Immunity against S. pneumoniae in Vaccinated Kidney Transplant Recipients
por: Gäckler, Anja, et al.
Publicado: (2021)

Validation of T-Track® CMV to assess the functionality of cytomegalovirus-reactive cell-mediated immunity in hemodialysis patients
por: Banas, Bernhard, et al.
Publicado: (2017)

Serum is not required for ex vivo IFN-γ ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program
por: Mander, A., et al.
Publicado: (2010)

Determining the Latent Tuberculosis Infection by IFN - γ Elispot Assay in Healthcare Workers From University Hospitals of Shiraz, South West of Iran
por: Taheri, Mohammad, et al.
Publicado: (2013)

Monitoring cell-mediated immune responses in AAV gene therapy clinical trials using a validated IFN-γ ELISpot method
por: Patton, Kathryn S., et al.
Publicado: (2021)

Prognostic factors and outcome of adult allogeneic hematopoietic stem cell transplantation patients admitted to intensive care unit during transplant hospitalization
por: Michel, Christian S., et al.
Publicado: (2019)

Response definition criteria for ELISPOT assays revisited
por: Moodie, Z., et al.
Publicado: (2010)

Comparative Multi-Donor Study of IFNγ Secretion and Expression by Human PBMCs Using ELISPOT Side-by-Side with ELISA and Flow Cytometry Assays
por: Hagen, Jodi, et al.
Publicado: (2015)

Longitudinal Assessment of an ELISPOT Test for Mycobacterium tuberculosis Infection
por: Hill, Philip C, et al.
Publicado: (2007)

Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT
por: Maecker, Holden T, et al.
Publicado: (2005)

ELISPOT Cell Analysis Assay: Searching for Extracellular Footprints
por: Kalyuzhny, Alexander E.
Publicado: (2011)

Increased Level of IFN-γ and IL-4 Spot-Forming Cells on ELISPOT Assay as Biomarkers for Acute Graft-Versus-Host Disease and Concurrent Infections
por: Hirayama, Masahiro, et al.
Publicado: (2012)

Harmonization and qualification of an IFN-γ Enzyme-Linked ImmunoSpot assay (ELISPOT) to measure influenza-specific cell-mediated immunity within the FLUCOP consortium
por: Waerlop, Gwenn, et al.
Publicado: (2022)

IFN-γ-Based ELISpot as a New Tool to Detect Human Infections with Borna Disease Virus 1 (BoDV-1): A Pilot Study
por: Eidenschink, Lisa, et al.
Publicado: (2023)

Reversion of the ELISPOT test after treatment in Gambian tuberculosis cases
por: Aiken, Alexander M, et al.
Publicado: (2006)

High Reproducibility of ELISPOT Counts from Nine Different Laboratories
por: Sundararaman, Srividya, et al.
Publicado: (2015)

ELISPOT assays and their diagnostic potential in Lyme disease and Lyme neuroborreliosis
por: Ettischer‐Schmid, N., et al.
Publicado: (2020)

Mobilization permits reliable ELISPOT detection of long-term memory T cells secreting IFN-γ, IL-4, IL-5, and IL-17 without in vitro expansion
por: Ghosh, Jaya, et al.
Publicado: (2013)

Equivalence of ELISpot Assays Demonstrated between Major HIV Network Laboratories
por: Gill, Dilbinder K., et al.
Publicado: (2010)

ELISPOT Refinement Using Spot Morphology for Assessing Host Responses to Tuberculosis
por: Sibley, Laura S., et al.
Publicado: (2012)

Defining ELISpot cut-offs from unreplicated test and control wells
por: Alexander, Neal, et al.
Publicado: (2013)

Role of ELISPOT Assays in Risk Assessment Pre- and Post-Kidney Transplantation
por: Zitzner, Jennifer R., et al.
Publicado: (2012)

Dissecting the T Cell Response: Proliferation Assays vs. Cytokine Signatures by ELISPOT
por: Anthony, Donald D., et al.
Publicado: (2012)

Stepping up ELISpot: Multi-Level Analysis in FluoroSpot Assays
por: Janetzki, Sylvia, et al.
Publicado: (2014)

How Can Elispot Add Information to Improve Knowledge on Tropical Diseases?
por: Lima-Junior, Josué da Costa, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_vb5l71cvbk8iedj54aakcuulft